(NASDAQ: DMAC) Diamedica Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Diamedica Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast DMAC's revenue for 2027 to be $477,840,609, with the lowest DMAC revenue forecast at $477,840,609, and the highest DMAC revenue forecast at $477,840,609. On average, 1 Wall Street analysts forecast DMAC's revenue for 2028 to be $1,742,939,692, with the lowest DMAC revenue forecast at $1,742,939,692, and the highest DMAC revenue forecast at $1,742,939,692.
In 2029, DMAC is forecast to generate $3,366,312,093 in revenue, with the lowest revenue forecast at $3,366,312,093 and the highest revenue forecast at $3,366,312,093.